Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Tables)

v3.7.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Patent And Technology License Agreement, Milestone Payments [Table Text Block]
Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows:
 
Phase
 
Amount
 
 
 
 
 
Commencement of Phase II Study for a licensed product
 
$
200,000
 
Commencement of Phase III Study for a licensed product
 
$
250,000
 
Filing of a New Drug Application for a licensed product
 
$
400,000
 
Receipt of market approval for a licensed product
 
$
500,000